1982 Annual Report

BOSTON BIOMEDICAL RESEARCH INSTITUTE

BOSTON BIOMEDICAL RESEARCH INSTITUTE

Contents

"Medical care is personal and in the present—biomedical research is impersonal and for the future. Both are needed but they are not interchangeable."

Robert H. Ebert, M.D., President, Milbank Memorial Fund.

REPORT OF THE PRESIDENT

John A. Shane

Despite a year during which many economic hardships and uncertainties affected a broad range of worldwide activities, Boston Biomedical Research Institute (BBRI) extended its realm of interests and strengthened its capacity for future development in a number of fundamental ways.

The Institute continued to conduct outstanding research—an accomplishment evidenced by its receipt of a high level of financial support from the National Institutes of Health (NIH) in a period of intensive competition for grants and reduced availability of grant funds.

The Development Office, Development Committee and others have worked hard to seek out and obtain contributions from philanthropies, individuals and corporations to supplement monies received from the Federal Government and voluntary health agencies. Efforts continue to be made to disseminate information about the value of the Institute's research programs and basic research in general, and to broaden BBRI's base of support. Considerable attention has been given to holding informational luncheons and other events at the Institute. In addition, this year three special events, including an evening at the theater, "The King and BBRI", and two springtime musical soirees in Waltham and South Hamilton brought new and old friends together to benefit the Institute. Through these many activities the Institute raised close to $94,000 for the General Fund this year.

Conservative management by BBRI's staff coupled with outstanding resource management by the Investment Committee kept the Institute financially sound and gave the Institute the means to accomplish much during the year. Some examples follow.

1. Underutilized space in the basement and on the third floor of the Institute's premises was fully renovated and equipped to provide more than 4,000 square feet of laboratory space. The cost of renovation was covered by generous grants from the Fred M. Roddy Foundation, Inc. and The Frederick J. Kennedy Memorial Foundation, Inc., and by donations made to the Institute's Building Fund. Construction of a comparable amount of new space would have cost up to fives times as much. An open house exhibiting these spaces and the research programs they accommodate was held on 20 May.



2. The Institute was able to attract Dr. Vladimir Z. Volloch, an outstanding scientist in the area of recombinant DNA, and to support Dr. Volloch's work until an NIH grant application could be submitted and approved.

3. The Institute was able to support several preliminary patent searches for staff members whose work appears to hold commercial promise.

4. Funds were made available to explore the feasibility of creating, financing and staffing a commercial subsidiary of BBRI that will attempt to develop selected Institute projects for business purposes. As a result of this study, in June the Board of Trustees authorized the creation of Boston Biotechnology Corporation (BBC), a wholly-owned subsidiary of BBRI. In September, a Memorandum of Understanding covering the proposed relationship between BBRI and BBC was signed.

Concurrent with the establishment of BBC, Polaroid Corporation began discussions regarding Polaroid's sponsorship of a research project conceived by Department Director Dr. Henry P. Paulus and of possible future involvement in commercializing this work if it proved feasible. These discussions culminated in an agreement between Polaroid, BBRI and BBC which is highlighted by the following provisions:

1. Polaroid granted a one-year $200,000 research contract to Dr. Paulus;

2. Polaroid received exclusive rights to commercialize Dr. Paulus' technology with royalties to be paid to BBC, BBRI and Dr. Paulus; and

3. Polaroid received an option to purchase a minority equity position in BBC, BBRI's subsidiary.

Accomplishments such as those described in this report do not occur easily or simply by money. They require endless hours of intelligent and constructive effort on the part of all the Institute's constituents. I should also like to cite the following individuals for their particularly outstanding contributions to the Institute this year:

1. Vice President John B. French, who spent endless hours negotiating and drafting the agreements between Polaroid, BBRI and BBC;

2. Vice President Eustis Walcott, Jr. for chairing an extremely productive and active Development Committee;

3. Treasurer Daniel A. Phillips for chairing the Investment Committee and for managing our resources so well during the year that the Trustees were able to finance the projects described above;

4. Corporator Horace W. Cole, who is never too busy to work for the Institute, who bubbles with good ideas, and who ably chaired the 1983 Nominating Committee; and

5. Trustee Elkan R. Blout and Corporator William R. Page for bringing BBRI's capabilities to the attention of Polaroid.

We would like to thank Mrs. Harborne W. Stuart for her able service on the Board of Trustees over the past four years. This year Chilton S. Cabot and John T. Trefry were welcomed to the Board of Trustees. Both longtime Corporation Members, they have each joined the rest of the Board in contributing time, enthusiasm and their own talents to the Institute. Jack, among other things, has been quick with a camera and is credited with some of the photographs included in this report. Finally, my appreciation and gratitude to all the Trustees and to those Corporators who were called to serve this year and who did so so magnificently.

REPORT OF THE EXECUTIVE DIRECTOR

D. Rao Sanadi, Ph.D.

As in the years past, the scientific activity of the Institute has been highly productive in 1982. Over fifty papers were published in established scientific journals and several of the staff have been invited to participate at national and international conferences. Dr. John Gergely is clearly becoming recognized as one of the 'elder statesmen' of muscle research. His honors and demanding responsibilities include chief editorship of the *Biophysical Journal* and membership in the Biophysical Chemistry Study Section of the National Institutes of Health (NIH). Dr. Jen-shiang Hong, a recent addition to the Institute staff, has been appointed to the Microbial Chemistry Study Section of the NIH. I serve as chief editor of the *Journal of Bioenergetics and Biomembranes*. The scientific merit of our staff is also demonstrated by the fact that our fiscal 1982 research budget grew eight percent over last year's despite intense competition for research grants.

Staff turnover this year has been unusually high and has included some of our senior members. Dr. Barbara Wright, former Director of the Department of Developmental Biology, left in May to become a Distinguished Professor of Biology at the University of Montana. Dr. Alexander Nussbaum, former Director of the Department of Bioorganic Chemistry, has joined the Department of Biological Chemistry at Harvard University on a full-time basis. In addition, Dr. Fred Julian, former Senior Staff Scientist in the Department of Muscle Research, has transferred his research program to the Peter Bent Brigham Hospital in order to participate in clinical work part-time.

Fortunately, our losses have been offset by some personnel gains. In an effort to enlarge the Institute's molecular biology program, we have recruited Dr. Vladimir Volloch from the Massachusetts Institute of Technology. He has initiated a program on the control of gene expression in leukemic cells. Other new staff members include Drs. Suresh Kaplay and Robert Burrows as Research Associates, and several Research Fellows.

Renovation of underutilized basement laboratories and unfinished space on the third floor is now complete. Among the activities housed in the improved areas is a new hybridoma facility, which is currently being used by several groups to produce monoclonal antibodies for research use. This facility will continue to be a valuable resource. Also located in the new space is Dr. Hong's group. His research on membrane transport involves the recombinant DNA approach.

Ever in the background of the Institute's achievements is the consistent decrease in federal funding for medical research. In 1980 Congress agreed to maintain the budget of the National Institutes of Health at a level sufficient to fund 5,000 new and competing research grants. In 1981, however, this number dropped to 4,700 grants and to 4,100 in 1982. The NIH budget proposed by the Administration for 1983 would have funded only 3,100 grants and reduced the reimbursement of overhead expenditure by ten percent. Fortunately, through the strenuous efforts of the academic community, some funds were restored, and no reduction in overhead reimbursement is expected.

The future of government funding for basic research is not promising. We are not likely to see again the rapid growth of the government's research budget that was seen in the 50s and early 60s. Undoubtedly, in the next two years there will be more efforts to reduce the NIH budget but also pressure to maintain at least the current funding level. Unfortunately, recognition that biomedical research is not a luxury and that it contributes significantly to better health and decreased medical expense is slow



in coming. Further, basic research has a direct impact on our gross national product (GNP) even if one excludes the pharmaceutical industry. A 1981 NIH report, "Biomedical Discoveries Adopted for Purposes Other Than Health Services", showed that ten discoveries contribute about 37 billion dollars annually to the GNP. This figure exceeds the total of all NIH appropriations since the agency's inception in 1937. Examples of discoveries affecting the GNP are enzyme detergents, home hair permanents and the use of fiber optics in telecommunications.

How much will the current biotechnology explosion contribute to the GNP and the future of health care? Estimates vary widely, but all agree it will be substantial. In any event, we hope that through our efforts here at the Institute and at other organizations like ours, the general public will come to recognize the cost effectiveness and manifold benefits of biomedical research.

In an effort to maintain the research momentum now threatened by reduced federal funding, many institutions have begun to seek industrial sponsorship because commercially valuable discoveries often arise as by-products of research. In turn, industry has recognized the tremendous market opportunities in biotechnology. In response to this trend several new ventures have been started. We are indeed grateful to our Board of Trustees for encouraging our staff to join the biotechnology exploration. Their wisdom in establishing the Boston Biotechnology Corporation, with the leadership of Mr. John Shane, as an entry into biotechnology is both timely and far-reaching. We realize, of course, that rewards, if any, from this enterprise, may be several years away.

Basic research to demonstrate the feasibility of Dr. Henry Paulus' pending patent application on new technologies using monoclonal antibodies will be financed by a research contract from Polaroid Corporation. This is the first significant contract from industry received by our Institute. It represents a great deal of work by BBRI's Trustees and staff and by individuals at Polaroid as well.

Our staff and lay supporters are all aware of the difficulties that may arise from accepting such industrial sponsorship. We are primarily a basic research institute, and the risks associated with industry-sponsored research include unnecessary secrecy and possible diversion of Institute facilities from our primary mission. We have, therefore, formalized the policy that requires the Committee on Research to review contracts from industry with the same criteria that apply to research grants. We also expect that results of this sponsored research will be published just like results of grant-supported research. Let me assure all our friends that there will be no compromise on quality and only meritorious projects will be undertaken.

In closing I wish to acknowledge the close interaction of our Trustees and the staff at several meetings and other events. The counsel and support that the Trustees and Corporate Members provide are a constant source of encouragement.

In 1982, Boston Biomedical Research Institute (BBRI) marked its 12th year as an independent, non-profit basic research institute. BBRI investigators, in cooperation and collaboration with other scientists around the world, are searching for fundamental clues to perplexing health problems. They carry out a broad program of basic and applied research in biology and medicine and provide specialized training for physicians and scientists from the United States and abroad. New knowledge garnered from such research is the starting point for all medical advances.



While 1970 is remembered as the year that Boston Biomedical Research Institute was established, the origins of the Institute and its family of friends actually date back thirty years to the establishment of the Retina Foundation. By the mid-1960s there was increasing emphasis on clinically-oriented eye research in addition to greater diversification of the basic research program directed toward understanding the "totality of the living organism."



The research activities were carried out under the banner of the Institute of Biological and Medical Sciences, Retina Foundation. Among the Directors of this organization were: Dr. Endre A. Balazs, Department of Connective Tissue; Dr. John Gergely, Department of Muscle Research; and Dr. D. Rao Sanadi, Department of Bioenergetics Research. Through the efforts of these men and others, research programs on human development and aging continued to grow.

To provide for optimal growth of both the eye research and the broader basic research program, scientists in the latter program formally separated from the Retina Foundation in 1970 to form Boston Biomedical Research Institute. Through an agreement with the Retina Foundation, BBRI continues to share facilities at 20 Staniford Street in Boston and the research farm in Townsend.

FACILITIES

BBRI's research facilities in downtown Boston are in a building shared with the Eye Research Institute of the Retina Foundation. Usable space of 25,000 square feet on four floors houses fully-equipped laboratories, computer facilities, an animal care center, a specialized research library, seminar rooms and offices. Recent renovations to existing space in the basement and third floor have provided 4,000 square feet of laboratories for hybridoma research, muscle research, computer facilities, and storage for flammable materials. Additional laboratory space and housing for large animals is available at the research farm in Townsend.







Computer Facilities

BBRI's computing facility is based on a Digital Equipment Corporation PDP-11/44 minicomputer. Through interfaces between the main computer and a variety of microcomputers and laboratory instruments, investigators are aided in acquiring data, creating model systems and performing complex analyses. In addition, both the scientific and support staff make great use of the system's word processing capabilities.



Hybridoma Laboratory

Recent renovations to the basement at BBRI included the construction of a sterile facility for hybridoma research. This promising technology involves fusing special tumor and antibody-producing cells to generate new cells which can produce highly specific antibodies. Monoclonal antibodies can identify and bind to particular types of proteins and cells, and provide a valuable research and diagnostic tool. The new facility has already enabled Institute researchers to explore the many possibilities of this exciting technology.

The unique strength of the Institute lies in its multidisciplinary nature, arising from the interaction of four departments: Muscle Research; Cell Physiology; Metabolic Regulation, dealing with internal cellular processes; and Fine Structure, concerned with the structure and molecular mechanisms in tissues. The Institute is small enough to assure collaboration, stimulation and cross-fertilization of ideas among these Departments, and vital enough to have gained international recognition.



Research Faculty

Over sixty percent of all BBRI staff hold advanced scientific degrees. Institute scientists are often invited to participate in international conferences to share their findings with colleagues. In the past year they contributed fifty articles to scientific journals and books, and many have served in editorial capacities for publications in the field of biomedical research and as reviewers for publications and Federal grant applications. These activities have made the Institute well known and respected in the world of science.



Teaching and Training

Most of the senior staff hold appointments at Harvard Medical School, and some are affiliated with Tufts New England Medical Center. In addition to teaching at area universities, senior staff share knowledge with aspiring young investigators through a training program at BBRI. Roughly one-fifth of the staff is in the post-doctoral phase of their careers.

Junior staff members often go on to develop their own research programs and secure their own support. Since 1977, nine junior staff members have become principal investigators, and all but one have remained at the Institute. BBRI provides the guidance and facilities for young scientists at the start of their professional careers.

Boston Biomedical Research Institute is unlike most non-profit research institutes in the United States. BBRI is not focussed on a single clinical area, but seeks to contribute to basic biomedical knowledge which finds application in a variety of fields, from heart and muscle disease to developmental and age-related degenerative diseases. These programs contribute to laying the groundwork for the prevention and cure of disease—much as early studies on viruses led to vaccines for polio and a number of other human and animal diseases.



While BBRI scientists are currently involved in close to thirty different research projects, the entire program of research is devoted to two major areas: muscle research and cell regulation studies. Two general principles describe research strategies behind specific projects:

1. The description of biological processes common to all living cells;
2. The explanation of living systems in terms of the structure and function of their constituent biological macromolecules.



Diseases and afflictions now under investigation at the Institute include:

- *Cancer*
- *Heart Disease*
- *Arthritis*
- *Connective Tissue Diseases*
- *Muscular Dystrophy*
- *Hypertension*
- *Arteriosclerosis*
- *Primary Biliary Cirrhosis*
- *Hormonal disorders*
- *Function and dysfunction in the aging process*





Collaboration

Institute staff work with individuals in many organizations, including: Massachusetts General Hospital, Harvard Medical School, Children's Hospital, Beth Israel Hospital, Massachusetts Eye and Ear Infirmary, New England Medical Center and the Retina Foundation. Collaboration has led to a direct clinical application in the case of Dr. Frank A. Sreter's current work with Dr. John Ryan, Chief of Pediatric Anesthesiology at Massachusetts General Hospital. Drs. Ryan and Sreter have developed a method of testing muscle biopsy samples to determine a patient's tendency to malignant hyperthermia prior to surgery. This inherited condition is life-threatening when a susceptible individual is given a certain type of anesthetic such as halothane. Through the sharing of knowledge, Drs. Sreter, Ryan and their colleagues have been able to determine the risk for many patients scheduled for surgery.

Grants

Many of the Institute's research and training activities are funded by grants from governmental agencies such as the National Institutes of Health (NIH) and the National Science Foundation (NSF). Despite increasing competition for disbursements from this source, total research funding at BBRI has remained high. This success in the highly competitive system of peer review is evidence of the quality and caliber of the research staff.

BBRI also receives funding from voluntary health agencies. Both the Muscular Dystrophy Association and the American Heart Association have been providing research support as well as training funds.



"Biomedical research and research training represent long term investments in personal health care and in the public health."

Robert H. Ebert, M.D., President, Milbank Memorial Fund.

FY 1978 FY 1982

FIVE YEAR COMPARISON SOURCE OF TOTAL FUNDS EXPENDED



***Includes expenditures of $150,434 from Building Fund for basement and third floor renovation.*

FY 1978 TOTAL FUNDS = $2,590,991

FY 1982 TOTAL FUNDS = $4,694,854

Private Support

Federal and voluntary health agency grants, however, fall short of providing full support for research programs and pilot investigations. Gifts from individuals, corporations and philanthropies help BBRI respond to emerging scientific opportunities, explore new fields, and assist in training scientists for future careers.

In a time of federal austerity, progress in basic biomedical research is becoming increasingly dependent upon the financial commitment of people who understand the value of the Institute's fundamental investigations. Through a variety of publications, special events and appeals, and with the help and guidance of dedicated Corporation Members and friends, BBRI continues to see a growth in both the number and value of donations from the private sector. The Institute is indeed grateful to all who make an investment in the future well-being of mankind.

THANK YOU

BBRI is extremely grateful to the individuals and institutions listed below who have made generous contributions during the fiscal year ended August 31st, 1982.

FOUNDATIONS

Anonymous
Anonymous
Connor Foundation, Inc.
Marie G. Dennett Foundation
Eaton Foundation
The Fuller Foundation, Inc.
G.E. Employees Good Neighbor Fund, River Works Plant
Haffenreffer Benevolent Corporation
Henderson Foundation
Walter R. & Helen P. Hennessey Charitable Foundation
The Mark Hyman Fund
The Mitchell B. Kaufman Charitable Foundation
Paine Charity Fund
G. Gorham Peters Testamentary Trust
Fred M. Roddy Foundation, Inc.
Alford P. Rudnick Family Fund of the Combined Jewish Philanthropies of Greater Boston, Inc.
Stop & Shop Foundation
The Tamarack Foundation

BUSINESSES

New England Nuclear Corporation
Sensor Diagnostics, Inc.
Solvents Recovery Service of New Jersey, Inc.
Vappi & Co., Inc.
E. T. Wright & Co., Inc.

BENEFACTORS

Horace W. Cole
Mrs. Charles M. Ewing
Mohandas M. Kini, M.D.
Charles E. Merrill
Mrs. John W. (Ruth H.) Scott
John A. Shane
Gilbert L. Steward, Jr.
Mrs. Henry (Olga M.) Wheeler, Jr.

SPONSORS

Chilton S. Cabot
David C. Crockett
Mrs. J. Howard Means
Kenneth Rainin
Mr. and Mrs. William B. Tyler

SUSTAINERS

Mike M. Coleman
Jean E. de Valpine
William Greene
Gordon F. Kingsley
Paul C. Leavis, Ph.D.
Stanley C. Paterson
Walter F. Stafford, III, Ph.D.
Charles P. Waite
Eustis Walcott, Jr.
Monte J. Wallace
Howland S. Warren

ASSOCIATES

Elkan R. Blout, Ph.D.
Samuel W. Bodman
Paul Boeder, Ph.D.
Mrs. Lillian M. Clancy
William H. Congleton
Dr. and Mrs. Peter F. Davison
Claes H. Dohlman, M.D.
Mr. and Mrs. William Elfers
W. Sidney Felton







Mrs. George P. Fogg, Jr.
John B. French
Mr. and Mrs. Ronald Garmey
Dr. and Mrs. John Gergely
Henry Gesmer
David A. Gibbs, Sc.D.
Francis W. Hatch, Jr.
James S. Hughes
Denholm M. Jacobs
Mr. and Mrs. Nathaniel C. Nash, Jr.
Mrs. John T.G. Nichols
William R. Page
Henry P. Paulus, Ph.D.
Daniel A. Phillips
Mr. and Mrs. Vincent F. Raso
D. Rao and Mary Jane Sanadi
Chester M. Sawtelle
Dale A. Schuparra
Eldon Scott
Dr. and Mrs. Irwin W. Sizer
Mr. and Mrs. Richard D. Stone
John T. Trefry
Norman R. Veenstra
Barbara E. Wright, Ph.D.

FRIENDS

Mr. and Mrs. Robert A. Baker
Mr. and Mrs. F. Gorham Brigham, Jr.
Robert B. Burrows, II, Ph.D.
Mr. and Mrs. Edward A. Caredis
Thelma B. Carter
Mr. and Mrs. Bigelow Crocker, Jr.
Ruth Emyanitoff, Ph.D.
Alan C. Fagan
Mr. and Mrs. Bradford K. Gallagher
Mr. and Mrs. Charles Mac K. Ganson
Irvin McD. Garfield, Jr.
H. Shippen Goodhue
Mr. and Mrs. T. McLean Griffin
Mrs. Leopold Gruener
Mrs. Miles Herter
Mrs. Deran S. Hintlian
Mr. and Mrs. Charles M. Hoyt, Jr.
Bernard Jacobson, Ph.D.
Roger W. Jeanloz, Ph.D.
Chloe T. N. Johnson
Prescott L. Kettell
Mr. and Mrs. J.N. Krebs
Sherwin S. Lehrer, Ph.D.
Caleb Loring, Jr.
Mr. and Mrs. John Lowell
Ralph Lowell, Jr.
Lynn Nathanson
Mr. and Mrs. H. Gilman Nichols, Jr.
Mr. and Mrs. Theodore A. Oatis
Theodora Perry
Richard L. Pharo
Mrs. Richard D. Phippen
Stephen W. Plimpton
Mrs. George R. Poor
Mrs. G. Glen Potter
Mr. and Mrs. Jerome Preston, Sr.
Mr. and Mrs. Charles M. Pyle, Jr.
Laurie W. Raymond, M.D.
Lenore T. Rothman
Myer Saxe
Dr. and Mrs. John C. Seidel
Margaret G. Shane
Mrs. Clifton A. Sibley
Sidney A. Slobodkin
Mr. and Mrs. Alan J. Stern
Mr. and Mrs. Alexander C. Stohn, Jr.
James H. Stone
Mrs. Harborne W. Stuart
Mr. and Mrs. Harry Syrigos
Mr. and Mrs. Richmond P. Warner
Mrs. Constance V. R. White
Hartmut Wohlrab, Ph.D.
Judy G. Zeprun

OFFICERS AND TRUSTEES

William B. Tyler
Chairman

John A. Shane
President

Mrs. Charles M. Ewing
Vice President

John B. French
Vice President

Eustis Walcott, Jr.
Vice President

Daniel A. Phillips
Treasurer

Ronald Garmey
Secretary-Clerk

D. Rao Sanadi, Ph.D.
Executive Director

John Gergely, M.D., Ph.D.
Deputy Executive Director

Elkan R. Blout, Ph.D.
Chilton S. Cabot
David C. Crockett
Ernest Henderson III
Denholm M. Jacobs
Mrs. J. Howard Means
Mrs. Nathaniel C. Nash, Jr.
Stanley C. Paterson
John T. Trefry

CORPORATION MEMBERS

Raymond D. Adams, M.D.
Endre A. Balazs, M.D.
Robert H. Binstock, Ph.D.
Paul Boeder, Ph.D.
Herbert Bremner
John M. Buchanan, Ph.D.
Horace W. Cole
Donald G. Comb, Ph.D.
William H. Congleton
Mrs. Bigelow Crocker, Jr.
Mrs. Nelson J. Darling, Jr.
Peter F. Davison, Ph.D.
Claes H. Dohlman, M.D.
Alan C. Fagan
W. Sidney Felton
David A. Gibbs, Sc.D.
H. Shippen Goodhue
Hamish F. Gravem
Jerome Gross, M.D.
Edgar Haber, M.D.
James S. Hughes
Roger W. Jeanloz, Ph.D.
Edward C. Johnson, 3rd
Manfred V. Karnovsky, Ph.D.
Mohandas M. Kini, M.D., Ph.D.
Joseph B. Martin, M.D.
Charles Merrill
Jeffrey L. Morby
James J. Myers
Mrs. John T. G. Nichols
Alexander Nussbaum, Ph.D.

William R. Page
Henry P. Paulus, Ph.D.
Mrs. Richard Phippen
Stephen W. Plimpton
Mrs. George Poor
John T. Potts, M.D.
Kenneth Rainin
Laurie W. Raymond, M.D.
Robert W. Selle
Irwin W. Sizer, Ph.D.
Sidney A. Slobodkin
Gilbert L. Steward, Jr.
Mrs. Harborne W. Stuart
Norman R. Veenstra
Charles P. Waite
Monte J. Wallace
Barbara E. Wright, Ph.D.

VISITING COMMITTEE

Robert A. Alberty, Ph.D.
George F. Cahill, Jr., M.D.
Mahlon B. Hoagland, M.D.

STAFF *(as of September 1, 1982)*

DEPARTMENTAL DIRECTORS

Peter F. Davison, Ph.D.
Fine Structure Research

John Gergely, M.D., Ph.D.
Muscle Research

Henry P. Paulus, Ph.D.
Metabolic Regulation

D. Rao Sanadi, Ph.D.
Cell Physiology

SENIOR STAFF SCIENTISTS

Eiji Fujimori, D.Sc.
Noriaki Ikemoto, Ph.D.
Sherwin S. Lehrer, Ph.D.
Satyapriya Sarkar, Ph.D.
John C. Seidel, Ph.D.
Frank A. Sreter, Ph.D., D.V.M., M.D.
Hartmut Wohlrab, Ph.D.

STAFF SCIENTISTS

Robert J. Fisher, Ph.D.
Philip Graceffa, Ph.D.
Cecilia Hidalgo, Ph.D.
Jen-shiang Hong, Ph.D.
Bernard Jacobson, Ph.D.
Saroj Joshi, Ph.D.
Kathleen A. Killick, Ph.D.
Paul C. Leavis, Ph.D.
Renne C. Lu, Ph.D.
Malcolm G. Pluskal, Ph.D.
Mario S. Rosemblatt, Ph.D.
Raman Kumar Roy, Ph.D.
Nilima Sarkar, Ph.D.
Walter F. Stafford, III, Ph.D.
Terence Tao, Ph.D.

RESEARCH ASSOCIATES

Paul Allen, M.D., Ph.D.
Maureen Brennan, Ph.D.
Robert B. Burrows, II, Ph.D.
Edward J. Galbavy, M.D., Ph.D.
James Hughes, Ph.D.
Suresh Kaplay, Ph.D.
Katsuhide Mabuchi, Ph.D.
Barbara Ann Manuck, Ph.D.
Michael Pringle, Ph.D.
Terrence Scott, Ph.D.

STAFF FELLOWS

Dipak Chakrabarty, Ph.D.
Yanamandra Gopalakrishna, Ph.D.
Zenon Grabarek, Ph.D.
Agnes Jancso, Ph.D.
B.C. Lakshmi Kantham, Ph.D.
Hanno V.J. Kolbe, Ph.D.
Jozsef Mandl, M.D., Ph.D.
Zoltan Marcsek, Ph.D.
Asok Mukherjee, Ph.D.
Sumitra Nag, Ph.D.
B.K. Ahmed Rasheed, Ph.D.
Katalin Torok, Ph.D.
Chih-Lueh Albert Wang, Ph.D.

RESEARCH FELLOWS

Do Han Kim, Ph.D.
Edward Morris, Ph.D.
Chandrika Saidapet, Ph.D.
Gale Strasburg, Ph.D.
Hiroshi Suzuki, Ph.D.









RESEARCH ASSISTANTS

Bozenia Antoniu, B.S.
Robert Bondaryk, A.B.
Cheryl L. Brown, B.S.
Adelaida D. Carlos, B.S.
Anne J. Collins, B.S.
Joseph E. Connolly, B.S.
Stefania Danko, M.S.
Rafi Dekermendjian, B.S.
Ramona Faris, B.S.
Dianne Goldrick, B.A.
M. Elena Gonzalez, M.S.
Elizabeth Gowell, B.S.
Jadwiga Grabarek, M.S.
David Griffiths, B.S.
Rebecca B. Kucera, M.S.
Deborah LaPenta
Laszlo Meszaros, M.S.
Remedios D. Nazareno, B.S.
Ralph W. Nelson, B.S.
Margaret E. O'Neil, B.S.
Martin K. Selig, B.A.
Rinehard Viehoff, B.S.
Anna G. Wong, B.A.

VISITING SCIENTISTS

Narindar Nath, Ph.D.
Alexander L. Nussbaum, Ph.D.

ADMINISTRATION

Vincent F. Raso, B.S., C.P.A.
Asst. Executive Director/Controller
Jean Ball
Financial Asst./Bookkeeper
Helene Clinton
Asst. Bookkeeper
Patricia Brouillette
Secretary

DEVELOPMENT

Penelope W. Stohn, M.P.A.
Development Officer
Anne F. Warner, B.A.
Development Assistant

DEPARTMENTAL ADMINISTRATION

Carol G. Burke, B.S.
Mary Caulfield
Angela J. DiPerri
Jenny L. Donovan
Susan Lee Karlson
Dorothy Syrigos, A.S.
Theresa Thompson

HOUSEKEEPING

Angela Barletta
Maria Bozzella
Shirley Eiland
Phuong Ngoc Huynh
Lucille Konjoian

BOSTON BIOMEDICAL RESEARCH INSTITUTE
Comparative Balance Sheet
August 31, 1982 and 1981

	1982					1981
	Unrestricted Funds		Restricted Funds	Plant Funds	Total All Funds	Total All Funds
ASSETS	Operating	Other				
Current assets:						
Cash	$ 5,925	$ 131,329	$	$	$ 137,254	$ 178,399
Grants receivable			3,046,220		3,046,220	3,232,854
Pledges receivable	25,000				25,000	125,000
Overhead & fringe benefit adjustment receivable			299,881		299,881	
Prepayments, deposits and other receivables	45,774				45,774	56,660
Investments, at market value (cost $988,637; $1,212,724)	13,920	786,703	197,220		997,843	1,176,396
Total current assets	90,619	918,032	3,543,321		4,551,972	4,769,309
Fixed assets: (See Notes 1 & 2)						
Leasehold improvements				1,933,411	1,933,411	1,776,977
Research equipment				2,888,109	2,888,109	2,639,118
Furniture and fixtures				47,129	47,129	47,129
Total				4,868,649	4,868,649	4,463,224
Less accumulated depreciation and amortization				2,262,433	2,262,433	1,902,586
Net fixed assets				2,606,216	2,606,216	2,560,638
Total assets	90,619	918,032	3,543,321	2,606,216	7,158,188	7,329,947
LIABILITIES AND FUND BALANCES						
Current liabilities:						
Accounts payable	4,013				4,013	12,793
Accrued expenses	40,000				40,000	40,000
Deferred grant income (See Note 4)			3,312,157		3,312,157	3,574,600
Deferred fund (building) (See Note 4)			231,164		231,164	336,168
Overhead & fringe benefit adjustment payable						37,970
Total current liabilities	44,013		3,543,321		3,587,334	4,001,531
Fund balances: (See Note 1)						
Operating	46,606				46,606	77,025
Equipment replacement		610,893			610,893	425,534
Permanent research		258,082			258,082	222,869
Building program		49,057			49,057	42,350
Fixed assets				2,606,216	2,606,216	2,560,638
Total fund balances	46,606	918,032		2,606,216	3,570,854	3,328,416
Total liabilities and fund balances	90,619	918,032	3,543,321	2,606,216	7,158,188	7,329,947

The accompanying notes are an integral part of these financial statements.

BOSTON BIOMEDICAL RESEARCH INSTITUTE
Comparative Statement of Revenues, Expenses and Changes in Fund Balances
For the Years Ended August 31, 1982 and 1981

	1982					1981
	Unrestricted Funds		Restricted	Plant	Total All	Total All
	Operating	Other	Funds	Funds	Funds	Funds
Revenues:						
Grants	$	$	$ 4,371,041	$	$ 4,371,041	$ 4,058,124
Equipment replacement		117,983			117,983	62,477
Contributions and pledges	92,794		157,459		250,253	96,348
Property and equipment purchased (See Notes 1 & 2)				405,425	405,425	278,999
Investment income	18,141	109,296	25,000		152,437	87,932
Total	110,935	227,279	4,553,500	405,425	5,297,139	4,583,880
Expenses: (by department)						
Muscle Research			2,538,423		2,538,423	2,199,502
Cell Physiology			837,734		837,734	683,136
Developmental Biology			285,963		285,963	318,741
Fine Structure			288,754		288,754	366,984
Metabolic Regulation			239,753		239,753	255,797
Bioorganic Chemistry			76,357		76,357	162,301
General Research	52,386		130,082		182,468	118,967
Fund Raising	36,081				36,081	26,012
Purchase of fixed assets	52,887		156,434		209,321	85,758
Depreciation and amortization (See Note 2)				359,847	359,847	306,344
Total	141,354		4,553,500	359,847	5,054,701	4,523,542
Net addition (deduction) to fund	(30,419)	227,279		45,578	242,438	60,338
Fund balances, begining of year (See Note 1)	77,025	690,753		2,560,638	3,328,416	3,268,078
Fund balances, end of year (See Note 1)	46,606	918,032		2,606,216	3,570,854	3,328,416

The accompanying notes are an integral part of these financial statements.

(1)—Summary of Significant Accounting Policies:

Fund Accounting

The accounts are maintained on the accrual basis and in accordance with the principles of fund accounting. Funds that have similar characteristics have been combined into the following fund groups:

* Unrestricted funds include two groups representing the portion of expendable funds available for support of operations: a) The operating fund includes unrestricted contributions and investment income less the cost of grants not reimbursed in full by granting agencies, and further reduced by transfers to other funds; b) Other unrestricted funds represent reserves transferred from the operating fund, and a building program fund derived from unrestricted contributions.

* Restricted funds represent resources restricted for research grants or building additions. These funds are deemed to be earned and reported as revenues when the Institute has incurred expenditures in compliance with the specific restrictions. Amounts received but not yet earned are reported as restricted deferred amounts (See Note 4).

* Plant funds represent the undepreciated cost of leasehold improvements, equipment and furniture and fixtures.

Other Matters

All income, gains, and losses arising from the sale, collection, or valuation at market of investments are allocated to the fund owning the assets.

A portion of the overhead chargeable to research grants is deemed to be reimbursement for equipment and is shown as an addition to the Equipment Replacement Fund. This amounted to $117,983 in 1982 ($62,477 in 1981). In addition, $52,887 of equipment was charged to the operating fund in the year ended August 31, 1982 and added to the plant fund.

(2)—Plant Assets and Depreciation:

Boston Biomedical Research Institute, under an agreement dated June 16, 1970, shares with Retina Foundation the use of research facilities for fifty years at 20 Staniford Street, Boston, and of a research farm in Townsend, Massachusetts.

The leasehold improvement asset category represents the cost of Boston Biomedical Research Institute's long-term leasehold in the building and improvements, and is being amortized over the 50-year lease term. The furniture and equipment categories represent, at cost, acquisitions from operating funds and restricted research grant awards. Depreciation is primarily on the straightline basis over the estimated ten year useful life of the assets. All depreciation and amortization is charged to the plant fund.

(3)—Government Grants:

All grant costs billed to the U.S. government and most private grants are subject to audit by the granting agency.

(4)—Changes in Deferred Restricted Amounts:

	Building Fund	Grants & Contracts	Total
Balance, beginning of year	$336,138	$3,574,600	$3,910,738
Additions:			
New grants awarded		4,108,598	4,108,598
Contributions and pledges		1,025	1,025
Investment income	51,460	25,000	76,460
	387,598	7,709,223	8,096,821
Deductions:			
Funds expended for designated purposes during year	156,434	4,397,066	4,553,500
Balance, end of year	$231,164	$3,312,157	$3,543,321

(5)—Investments:

Investments consist of corporate and government bonds and listed stocks except for one new $800 investment made in 1982 in Boston Biotechnology Corporation. This company was formed to utilize and commercialize certain technical processes originated at Boston Biomedical Research Institute and elsewhere. The investment holding represents the entire outstanding stock of Boston Biotechnology Corporation and is shown at cost since Boston Biotechnology was inactive through Boston Biomedical Research Institute's year end.

GREENE & COMPANY/*Certified Public Accountants*, P.C.
2 Summer St./Natick/Mass. 01760/(617) 237-1687/(617) 655-7425

Board of Trustees
Boston Biomedical Research Institute
Boston, Massachusetts

We have examined the balance sheet of Boston Biomedical Research Institute as of August 31, 1982 and the related statement of revenues, expenses and changes in fund balances. Our examination was made in accordance with generally accepted auditing standards and accordingly included such tests of the accounting records and such other auditing procedures as we considered necessary in the circumstances. We made a similar examination for the preceding year.

In our opinion, the accompanying financial statements present fairly the financial position of Boston Biomedical Research Institute at August 31, 1982, and the results of its operations and changes in fund balances for the year then ended, in conformity with generally accepted accounting principles applied on a basis consistent with that of the preceding year.

October 8, 1982

Greene & Company

DESIGN:
Tacie McKittrick
PHOTOGRAPHY:
Creative Visions
and
John T. Trefry
EDITING:
BBRI Development Office
and
Ronald E. Akie

BOSTON BIOMEDICAL RESEARCH INSTITUTE
20 Staniford Street
Boston, Massachusetts 02114
Tel. (617) 742-2010